HRP20161236T1 - Kompozicija kaspofugina - Google Patents
Kompozicija kaspofugina Download PDFInfo
- Publication number
- HRP20161236T1 HRP20161236T1 HRP20161236TT HRP20161236T HRP20161236T1 HR P20161236 T1 HRP20161236 T1 HR P20161236T1 HR P20161236T T HRP20161236T T HR P20161236TT HR P20161236 T HRP20161236 T HR P20161236T HR P20161236 T1 HRP20161236 T1 HR P20161236T1
- Authority
- HR
- Croatia
- Prior art keywords
- caspofungin
- pharmaceutically acceptable
- mixture according
- formulation
- excipients
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38433310P | 2010-09-20 | 2010-09-20 | |
| PCT/EP2011/066202 WO2012038371A1 (en) | 2010-09-20 | 2011-09-19 | Caspofungin composition |
| EP11761049.3A EP2618814B1 (en) | 2010-09-20 | 2011-09-19 | Caspofungin composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161236T1 true HRP20161236T1 (hr) | 2016-11-18 |
Family
ID=44677877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161236TT HRP20161236T1 (hr) | 2010-09-20 | 2011-09-19 | Kompozicija kaspofugina |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20120101030A1 (enExample) |
| EP (1) | EP2618814B1 (enExample) |
| JP (1) | JP5914486B2 (enExample) |
| KR (1) | KR20130136466A (enExample) |
| CN (1) | CN103118663A (enExample) |
| AU (1) | AU2011304408B2 (enExample) |
| CA (1) | CA2810112A1 (enExample) |
| DK (1) | DK2618814T3 (enExample) |
| ES (1) | ES2593727T3 (enExample) |
| HR (1) | HRP20161236T1 (enExample) |
| HU (1) | HUE030464T2 (enExample) |
| IL (1) | IL225339A0 (enExample) |
| MX (1) | MX2013003045A (enExample) |
| PL (1) | PL2618814T3 (enExample) |
| PT (1) | PT2618814T (enExample) |
| RS (1) | RS55216B1 (enExample) |
| RU (1) | RU2013114993A (enExample) |
| UA (1) | UA111599C2 (enExample) |
| WO (1) | WO2012038371A1 (enExample) |
| ZA (1) | ZA201302113B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103212059A (zh) * | 2012-01-18 | 2013-07-24 | 江苏恒瑞医药股份有限公司 | 含有抗真菌药物和乳酸盐缓冲液的组合物 |
| CN103212058A (zh) * | 2012-01-18 | 2013-07-24 | 江苏恒瑞医药股份有限公司 | 含有抗真菌药物和乳酸盐缓冲剂的组合物 |
| US9636407B2 (en) * | 2012-11-20 | 2017-05-02 | Fresenius Kabi Usa, Llc | Caspofungin acetate formulations |
| CN103142997A (zh) * | 2013-03-13 | 2013-06-12 | 浙江海正药业股份有限公司 | 含有抗真菌剂和琥珀酸盐缓冲液的药物组合物 |
| KR20140123782A (ko) * | 2013-04-15 | 2014-10-23 | 에스케이케미칼주식회사 | 카스포펀진 및 완충제를 포함하는 안정성이 개선된 약학적 조성물 |
| CN104116716A (zh) * | 2013-04-25 | 2014-10-29 | 四川海思科制药有限公司 | 一种含卡泊芬净的冻干粉针剂药物组合物 |
| EP3054924B1 (en) * | 2013-10-07 | 2020-11-25 | Galenicum Health S.L.U. | Stable pharmaceutical formulations of caspofungin |
| GR1008818B (el) * | 2015-05-22 | 2016-08-01 | Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων | Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα εχινοκανδινης και μεθοδος παρασκευης αυτου |
| CN108760937B (zh) * | 2018-07-27 | 2020-12-29 | 杭州华东医药集团新药研究院有限公司 | 醋酸卡泊芬净中残留乙二胺的测定及其应用 |
| CN109758426B (zh) * | 2019-01-24 | 2021-04-27 | 四川制药制剂有限公司 | 一种注射用醋酸卡泊芬净药物组合物及其制备方法 |
| CN110859950B (zh) * | 2019-11-25 | 2021-08-10 | 武汉大学 | 一种用于白念珠菌棘白菌素类药物耐药菌的药物组合物及其应用 |
| EP4364566A1 (en) * | 2022-11-04 | 2024-05-08 | B. Braun Melsungen AG | Anti-fungal composition |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991015121A1 (en) * | 1990-03-30 | 1991-10-17 | Smithkline Beecham Corporation | Method for treating fungal infection |
| JP2930823B2 (ja) | 1991-12-11 | 1999-08-09 | 株式会社東芝 | Ｘ線ｃｔスキャナ用検出器及びｘ線検出装置用シンチレータチャネルセパレータ |
| US5378804A (en) | 1993-03-16 | 1995-01-03 | Merck & Co., Inc. | Aza cyclohexapeptide compounds |
| US5952300A (en) | 1996-04-19 | 1999-09-14 | Merck & Co., Inc. | Antifungal compositions |
| US20080046580A1 (en) | 2006-06-29 | 2008-02-21 | Nokia Corporation | Account creation system and call processing system |
| CN101516387B (zh) * | 2006-07-26 | 2014-06-04 | 桑多斯股份公司 | 卡泊芬净制剂 |
| BRPI0715113A2 (pt) * | 2006-07-26 | 2013-06-04 | Sandoz Ag Sandoz Sa Sandoz Ltd | formulaÇço de caspofungina |
| EP2170362B1 (en) | 2007-06-26 | 2015-11-04 | Merck Sharp & Dohme Corp. | Lyophilized anti-fungal composition |
| EP2285236A1 (en) * | 2008-05-30 | 2011-02-23 | DSM IP Assets B.V. | Use of succinic acid |
| US20090324635A1 (en) | 2008-06-25 | 2009-12-31 | Ferenc Korodi | Caspofungin free of caspofungin impurity A |
-
2011
- 2011-09-19 HR HRP20161236TT patent/HRP20161236T1/hr unknown
- 2011-09-19 HU HUE11761049A patent/HUE030464T2/en unknown
- 2011-09-19 UA UAA201304481A patent/UA111599C2/uk unknown
- 2011-09-19 CN CN2011800451119A patent/CN103118663A/zh active Pending
- 2011-09-19 RS RS20160810A patent/RS55216B1/sr unknown
- 2011-09-19 MX MX2013003045A patent/MX2013003045A/es active IP Right Grant
- 2011-09-19 RU RU2013114993/15A patent/RU2013114993A/ru not_active Application Discontinuation
- 2011-09-19 KR KR1020137010070A patent/KR20130136466A/ko not_active Ceased
- 2011-09-19 JP JP2013528699A patent/JP5914486B2/ja not_active Expired - Fee Related
- 2011-09-19 PL PL11761049T patent/PL2618814T3/pl unknown
- 2011-09-19 CA CA2810112A patent/CA2810112A1/en not_active Abandoned
- 2011-09-19 ES ES11761049.3T patent/ES2593727T3/es active Active
- 2011-09-19 AU AU2011304408A patent/AU2011304408B2/en not_active Ceased
- 2011-09-19 WO PCT/EP2011/066202 patent/WO2012038371A1/en not_active Ceased
- 2011-09-19 DK DK11761049.3T patent/DK2618814T3/en active
- 2011-09-19 EP EP11761049.3A patent/EP2618814B1/en active Active
- 2011-09-19 PT PT117610493T patent/PT2618814T/pt unknown
- 2011-09-20 US US13/237,193 patent/US20120101030A1/en not_active Abandoned
-
2013
- 2013-03-19 IL IL225339A patent/IL225339A0/en unknown
- 2013-03-20 ZA ZA2013/02113A patent/ZA201302113B/en unknown
-
2014
- 2014-11-19 US US14/547,742 patent/US9393307B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130136466A (ko) | 2013-12-12 |
| AU2011304408A1 (en) | 2013-03-28 |
| ES2593727T3 (es) | 2016-12-12 |
| US20150072923A1 (en) | 2015-03-12 |
| AU2011304408B2 (en) | 2015-01-15 |
| CA2810112A1 (en) | 2012-03-29 |
| EP2618814B1 (en) | 2016-07-27 |
| ZA201302113B (en) | 2014-05-28 |
| IL225339A0 (en) | 2013-06-27 |
| US20120101030A1 (en) | 2012-04-26 |
| UA111599C2 (uk) | 2016-05-25 |
| RU2013114993A (ru) | 2014-10-27 |
| WO2012038371A1 (en) | 2012-03-29 |
| PT2618814T (pt) | 2016-10-06 |
| HUE030464T2 (en) | 2017-05-29 |
| JP5914486B2 (ja) | 2016-05-11 |
| US9393307B2 (en) | 2016-07-19 |
| EP2618814A1 (en) | 2013-07-31 |
| JP2013537212A (ja) | 2013-09-30 |
| MX2013003045A (es) | 2013-06-24 |
| RS55216B1 (sr) | 2017-02-28 |
| CN103118663A (zh) | 2013-05-22 |
| DK2618814T3 (en) | 2016-10-10 |
| PL2618814T3 (pl) | 2017-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013537212A5 (enExample) | ||
| JP5914486B2 (ja) | カスポファンギン組成物 | |
| CA2753641C (en) | Bendamustine cyclopolysaccharide compositions | |
| CN102614491B (zh) | 一种含有棘白菌素类抗真菌剂米卡芬净的药用组合物及其制备方法和用途 | |
| US9937122B2 (en) | Palonosetron oral transmucosal film or patch | |
| RU2745070C1 (ru) | Частица и фармацевтическая композиция, содержащая нерастворимое соединение камптотецина, имеющая двойную структуру ядро-оболочка, и способ ее получения | |
| JP5723031B2 (ja) | エキノカンジン系抗真菌剤であるミカファンギンを含む液体薬用組成物 | |
| WO2013112762A4 (en) | Bendamustine compositions and methods therefore | |
| WO2011161531A4 (en) | Pharmaceutical composition containing goserelin for in-situ implant | |
| CA2715832A1 (en) | Topotecan ready to use solutions | |
| KR101889878B1 (ko) | 적하 가능한 안과용 비마토프로스트 겔 | |
| US20110207764A1 (en) | Cyclopolysaccharide compositions | |
| WO2017073798A1 (ja) | 鼻粘膜投与用医薬組成物 | |
| WO2022083729A1 (en) | Compositions of anti-viral peptides and/or compounds and methods of use thereof | |
| CN104043103B (zh) | 一种多黏菌素e甲磺酸钠冻干制剂及其制备方法 | |
| CN103211755A (zh) | 无菌稳定的阿奇霉素滴眼液的生产方法 | |
| CN101474164A (zh) | 一种口服复方紫杉醇胶囊剂及制备方法 | |
| CN102614493B (zh) | 一种含有棘白菌素类抗真菌剂卡泊芬净的液体药用组合物 | |
| WO2008089709A3 (en) | Oxaliplatin pharmaceutical composition with alcoholic sugar-based buffer | |
| CN103462906B (zh) | 一种注射用多西他赛纳米粒及其制备方法 | |
| CN104116706A (zh) | 一种丙酮酸乙酯滴眼液及其制备方法 | |
| CN104739807A (zh) | 一种总蟾毒内酯纳米胶束制剂及其制备方法 | |
| WO2011101865A2 (en) | Stable pharmaceutical compositions of clopidogrel for parenteral delivery |